Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flecainide inhalation - InCarda Therapeutics

Next Previous
Drug Profile

Flecainide inhalation - InCarda Therapeutics

Alternative Names: Flecainide acetate inhalation solution; FlecIH-101; FlecIH-103; FlecIH-104; Inhaled flecainide - InCarda Therapeutics; InRhythm™

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InCarda Therapeutics
  • Class Benzamides; Class Ic antiarrhythmics; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Paroxysmal atrial fibrillation

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Paroxysmal atrial fibrillation(In volunteers) in Australia (Inhalation, Liquid)
  • 30 Aug 2024 Efficacy and adverse events data from the phase III RESTORE-1 trial in Paroxysmal atrial fibrillation presented at the Annual Congress of the European Society of Cardiology (ESC Congress-2024)
  • 09 Jun 2023 InCarda Therapeutics terminates the Phase-III RESTORE-1 clinical trial in Paroxysmal atrial fibrillation (Newly diagnosed) in USA, Spain, Poland, Hungary, Czech Republic, Netherlands (Inhalation, Liquid) due to limited efficacy upon blinded review (NCT05039359) (EudraCT2021-001627-40)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top